



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/02, 39/40, 39/108, 39/395, C12N 5/00, 5/02, 5/06, C12P 21/04	A1	(11) International Publication Number: WO 99/59629 (43) International Publication Date: 25 November 1999 (25.11.99)
(21) International Application Number: PCT/US99/11179 (22) International Filing Date: 19 May 1999 (19.05.99) (30) Priority Data: 60/086,570 20 May 1998 (20.05.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/086,570 (CIP) Filed on 20 May 1998 (20.05.98) (71) Applicants (for all designated States except US): TEIJIN LIMITED [JP/JP]; 6-7, Mnamihommachi 1-chome, Chuo-ku, Osaka-shi, Osaka (JP). PROTEIN DESIGN LABS, INC. [US/US]; 34801 Campus Drive, Fremont, CA 94555 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): MATSUMOTO, Yoh-ichi [JP/JP]; 7-9-105, Tatenochi, Nerimaku, Tokyo 177-0054 (JP). IMAIZUMI, Atsuchi [JP/JP]; 5-10-8, Nishi-Hirayama, Hino City, Tokyo 191-0055 (JP). KIMURA, Tsuyoshi [JP/JP]; 2-19-2-401, Asahigaoki, Hino City, Tokyo 191-0065 (JP). TAKEDO, Tae [JP/JP]; 2-1-3, Nukui-kitamachi, Koganei City, Tokyo 184-0015		(JP). CO, Man, Sung [US/US]; 10952 Wilkinson Avenue, Cupertino, CA 95014 (US). VASQUES, Maximiliano [CR/US]; 3813 Louis Road, Palo Alto, CA 94303 (US). (74) Agents: LIEBESCHUETZ, Joe et al.; Townsend and Townsend and Crew LLP, 8th floor, Two Embarcadero Center, San Francisco, CA 94111-3834 (US). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: HUMANIZED ANTIBODIES THAT RECOGNIZE VEROTOXIN II AND CELL LINE PRODUCING SAME		
(57) Abstract The invention provides humanized antibodies that specifically bind to, and preferably, neutralize, verotoxin II (VT2). The antibodies are useful for treating patients suffering from, or at risk of suffering, toxic effects of verotoxin.		